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Background: To analyze the two-years effectiveness and safety of Resolute zotarolimus-eluting stents (R-ZES) implanted in ST segment elevation 
acute myocardial infarction (STEMI) versus in acute coronary syndrome without ST segment elevation (non-STEACS) versus in stable forms of 
coronary artery disease (st.CAD).
Methods: A pooled analysis from the RESOLUTE global program (Resolute All Comers and RESOLUTE International) revealed a total of 3011 
patients with R-ZES implantation for one of the three distinct indications: (a) STEMI within 24 hours (n = 335), (b) non-STEACS (n =1416) and (c) 
st.CAD (n = 1260).
Results: Mean age was 59.8 ± 11.3 years (STEMI) vs 63.8 ± 11.6 (non-STEACS) vs 64.9 ± 10.1 (st.CAD). STEMI pts less frequently had diabetes 
(19.1% vs 28.5% vs 29.2%), less prior infarctions (11.3% vs 27.2% vs 29.4%) and less previous revascularizations (11.3% vs 27.9% vs 37.6%). The 
outcomes for all three groups after 30 days, 1 year and 2 years with focus on stent thrombosis (ST) are in the table 1. The differences in the table 
are not significant (p values between 0,068 - 1,000) with two exceptions:*p= 0.016, **p = 0.012.
Conclusion: R-ZES implantation in the acute phase of STEMI is safe and the long term outcomes are favorable. Late and very late stent thrombosis 
(up to 2 years) is extremely rare (<1%) with R-ZES implantation irrespective of the original indication. 
Results
STEMI (n=335) nonSTEACS (n=1416) Stable CAD (n=1260)
2-years mortality 2.1% 4.8% 3.7%
2-years re-infarction 2.7% 5.0% 4.5%
Stent thrombosis (ARC def/prob) 0-30 days 1.8% 0.6% 0.7%
ST 31-180 days 0 0.3% 0.1%
ST 181-360 days 0.6% 0.1% 0.1%
ST 361-720 days 0 0.2% 0.2%
Clinically driven TVR 0-360 days 6.6% 4.2% 4.4%
Clinically driven TVR 361-720 days * 0.3% 2.6% 2.5%
Death or target vessel re-infarction 0-720 days ** 3.9% 8.7% 7.3%
